UK chronic obstructive pulmonary disease patients will be cheered by the news that Pfizer has signed a deal to promote two new drugs developed by Novartis.
The therapies in question are Seebri (glycopyrronium) and Ultibro (indacaterol/glycopyrronium) delivered through Novartis’ Breezhaler device. While the former has been available in the UK market since November 2012, Ultibro, which has a European licence, has not yet been launched.
Hey, check out all the research scientist jobs. Post your resume today!
